AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

On March 11, 2022 AbbVie (NYSE: ABBV) and Gedeon Richter Plc. (‘Richter’) reported a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases (Press release, AbbVie, MAR 11, 2022, View Source [SID1234609953]). The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In collaboration with Richter, we will continue to build on our research that seeks to provide additional insights into our understanding of cariprazine’s clinical pharmacology and explore novel chemistry to identify new dopamine receptor modulators," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "AbbVie is committed to driving progress and finding solutions for patients living with complex neuropsychiatric conditions."

"I am very pleased to extend our existing co-operation under this new collaboration with AbbVie as it opens the way towards new products that could help alleviate the debilitating psychiatric and cognitive symptoms of many neuropsychiatric conditions, leading to an improved quality of life for patients suffering from these conditions around the world," said Gábor Orbán, CEO of Richter. "I greatly value AbbVie’s capabilities in the field of development and commercialization of drugs acting on the Central Nervous System and we are looking forward to entering this collaboration on new therapeutic options for patients and doctors."

Under the terms of the agreement, the collaboration includes both preclinical and clinical R&D activities with shared financing by the parties. Richter will receive an upfront cash payment, along with potential future development, regulatory and commercialization milestones. In addition, Richter may also receive sales-based royalties. AbbVie will have worldwide commercialization rights except for traditional markets of Richter, such as geographic Europe, Russia, other CIS countries and Vietnam.

The transaction is expected to close in the second quarter of 2022, subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination

On March 10, 2022 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company for Lilly’s anti-EGFR antibody cetuximab (ERBITUX) (Press release, Erasca, MAR 10, 2022, View Source [SID1234639380]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This agreement will support the ongoing Phase 1b/2 HERKULES-3 trial, a clinical proof-of-concept study evaluating ERAS-007, an oral ERK1/2 inhibitor, in various combinations, including with the BRAF inhibitor encorafenib (BRAFTOVI) and cetuximab for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). Erasca will sponsor the study, and Lilly will supply cetuximab at no cost. The two companies will form a joint committee to review the clinical trial results.

"We are grateful to Lilly for their collaboration as we explore the therapeutic potential of adding ERAS-007, our intermittently-dosed ERK1/2 inhibitor, to the current standard of care regimen for this patient population," said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. "We expect the long-term benefits seen with current standard of care may be limited due to resistance mechanisms, particularly through MAPK reactivation. ERAS-007 inhibits the terminal node of the MAPK pathway and, based on preclinical models, offers more robust inhibition of MAPK reactivation over MEK and other ERK inhibitors. Additionally, ERAS-007’s pharmacokinetic and tolerability profile positions it well for combinations."

There are approximately 180,000 people, representing approximately 10% of all patients with CRC globally, who have BRAF V600E mutations. The combination of encorafenib plus cetuximab significantly improved overall survival in patients with mCRC with a BRAF V600E mutation compared to the control arm. Those clinical results also showed that 20% of patients experience an objective response and half of these responses last more than four months. Therefore, emergence of resistance is a major therapeutic barrier to long-term clinical benefit. Erasca is exploring whether ERK inhibition with ERAS-007 in combination with encorafenib plus cetuximab can reduce the emergence of resistance and further improve treatment benefit for patients with BRAF V600E CRC.

About ERAS-007
ERAS-007 is a potential best-in-class ERK1/2 inhibitor being investigated alone or in combination with different inhibitors targeting upstream nodes of the MAPK pathway as part of our MAPKlamp strategy. The extracellular signal-regulated kinases (ERK), ERK1 and ERK2, belong to a family of serine-threonine kinases that regulate cellular signaling and comprise the terminal node of the RAS/MAPK pathway. ERAS-007 is being investigated across a series of four HERKULES clinical trials that span multiple tumor types and include both monotherapy and combinations with approved and investigational agents, such as RTK, SHP2, RAS, RAF, and/or cell cycle inhibitors. HERKULES-1 is a Phase 1b/2 clinical trial for ERAS-007 as a single agent and in combination with the SHP2 inhibitor ERAS-601 in advanced solid tumors. HERKULES-2 is a Phase 1b/2 clinical trial for ERAS-007 in combination with various agents in patients with non-small cell lung cancer. HERKULES-3 is a Phase 1b/2 clinical trial for ERAS-007 in combination with various agents in patients with gastrointestinal cancers. HERKULES-4 is a Phase 1b/2 clinical trial for ERAS-007 in combination with various agents in patients with hematologic malignancies.

Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma

On March 10, 2022 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC) (Press release, Allogene, MAR 10, 2022, View Source [SID1234613688]). The FDA granted FTD based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinomas (RCC) who have failed standard RCC therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RCC is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low. The five-year survival rate for patients with advanced kidney cancer is less than 15%1.

"Metastatic solid tumors have historically been a challenge to treat regardless of treatment modality, creating a large unmet need for patients and a necessity for scientific innovation," said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer. "We have our sights set on confronting solid tumors where the need is unquestionably high. We remain optimistic for the potential of our AlloCAR T platform to address the challenge and we look forward to generating data from our ongoing Phase 1 trial."

ALLO-316 targets CD70, which is highly expressed in RCC with limited normal tissue expression, making it an attractive CAR T. CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors. The ongoing Phase 1 TRAVERSE trial is designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell RCC.

Fast Track designation is designed to accelerate the development and review of treatments for serious and life-threatening diseases where no treatment exists or where the treatment in discovery may be better than what is currently available.

Company Name Change: Shorla Pharma is now Shorla Oncology!

On March 10, 2022 Shorla Pharma reported that Our new name is better suited to our mission of re-thinking, re-imagining, and improving on existing, proven oncology treatments (Press release, Shorla Pharma, MAR 10, 2022, View Source;utm_medium=rss&utm_campaign=company-name-change-shorla-pharma-is-now-shorla-oncology [SID1234610027]). Shorla Oncology remains committed to the field of oncology and bringing our products to patients in need.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Compelling Preclinical Kidney Cancer Results for Zantrene

On March 10, 2022 Race Oncology Limited ("Race") reported that final results from the clear cell renal cell carcinoma (a dangerous form of kidney cancer) preclinical program led by eminent cancer researcher, Associate Professor Nikki Verrills of The University of Newcastle and Hunter Medical Research Institute (ASX announcement: 25 March 2021) (Press release, Race Oncology, MAR 10, 2022, View Source [SID1234610002]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This research found that Zantrene on its own and in combination with known kidney cancer drugs can kill kidney cancer cells at clinically relevant concentrations. These results support advancing Zantrene into the clinic as a possible new treatment option for advanced kidney cancer patients.

Figure 1. Human clear cell renal cell carcinoma (kidney cancer). Image courtesy of Wikipedia. Chief Scientific Officer, Dr Daniel Tillett said: "The results from Prof Verrills laboratory are highly encouraging and supportive of our clinical plans for Zantrene in kidney cancer. Advanced kidney cancer has a large unmet need for improved treatment options and Zantrene in combination with existing treatments may offer new hope for patients with this devastating disease." Chief Executive Officer, Mr Phillip Lynch said, "We are again pleased to note Zantrene’s effectiveness both in isolation and in combination with other known kidney cancer treatments.

This result encourages clinical translation, and we look forward to determining an optimal approach for progressing clinical study." Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com 2 Study Background Clear Cell Renal Cell Carcinoma Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, comprising over 70% of renal tumours (Figure 2). While a relatively rare cancer, accounting for approximately 2% of global cancer diagnoses and deaths, it has more than doubled in incidence over the past half-century, and today is the ninth most common cancer in the developed world1.

Figure 2. Kidney cancer types and relative incidence. Image courtesy of Wikipedia. Advanced/metastatic clear cell renal cell carcinoma occurs in 25–30% of people before diagnosis. The clinical signs of ccRCC are often mild or non-existent until the disease has spread throughout the body (metastasis)2. The most common organs for ccRCC to metastasize to lymph nodes, lungs, bones, liver and brain3. Late diagnosis remains a major challenge in the effective treatment of ccRCC. Treatment of Clear Cell Renal Cell Carcinoma Advanced ccRCC has a poor prognosis compared to many other cancers. While there have been major improvements in kidney cancer treatment in recent years, including the recent approval of immune therapies, the five-year survival rate for advanced ccRCC is still as low as 12%4.

New treatments and drug combinations remain urgently needed to address what is often a devastating disease. Importance of FTO in Clear Cell Renal Carcinoma A recent preclinical study identified a synthetically lethal interaction between the Von Hippel‐Lindau (VHL) tumour suppressor protein and the m6 A RNA demethylase Fatso/Fat Mass and Obesity Protein (FTO), in ccRCC5. Synthetic lethality occurs when the loss of either one of a pair of genes or proteins has little or no effect on the survival of the cell, but the loss of both proteins (or their activity) at the same time is lethal. Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com 3 VHL is inactivated in the majority of ccRCC (~90%)6, suggesting that the loss of FTO activity could prove lethal to cells lacking a functional FTO protein. Xiao et al found that FTO expression is increased in VHL-deficient ccRCC tumours, and genetic inactivation of FTO reduced the growth and survival of VHL-deficient cells5. Zantrene has been recently identified as a potent inhibitor of FTO7 so may prove efficacious in the treatment of ccRCC with inactive VHL genes. This hypothesis was tested using Zantrene on an isogenic VHL mutant and wildtype ccRCC cell line.

The potential for synergies with Zantrene and existing kidney cancer treatments was also explored.Study Highlights 1. Zantrene kills clear cell renal cell carcinoma cells The sensitivity of kidney cancer and normal kidney cell lines to Zantrene was tested as a single agent to determine the cytotoxicity IC50 (drug concentration required to kill 50% of cells). Zantrene cytotoxicity was measured using a resazurin assay combined with visual inspection of the cells at each dose level and the IC50 values calculated.

Direct cytotoxicity IC50 values ranged from 242nM to 12,353nM in the kidney cancer cell lines tested (Table 1). With the exception of the ccRCC A-704 cells, which were highly resistant, all other lines showed IC50 values below 1.4µM with 7 of the 12 lines displaying IC50 values below 1µM, a concentration achievable in patients based on prior human trials.To determine if VHL status (i.e. wildtype or mutant/deleted) was associated with increased sensitivity to Zantrene, the isogenic cell lines RCC4 EV, which has a mutant VHL gene and the RCC4 VHL cell line which has been transduced with the wildtype VHL gene to rescue the VHL loss, showed that the VHL mutant cell line was more sensitive (1.3x) to Zantrene than the VHL rescue line (Figure 3).2. Zantrene slows the growth of ccRCC cells Greater lethality between VHL loss and Zantrene was observed using long term clonogenic cell growth assays (cell colony formation), which better measures a drug’s effect on cancer cell growth rather than cell killing5.

The clonogenic assays were performed on the same panel of renal cell lines. A representative example of the effect of Zantrene on ccRCC cell colony formation is shown in Figure 4. Figure 4. Clonogenic cell growth assay of Zantrene in RCC4 EV cells. RCC4 EV cells were seeded in 6-well plates at 1000 cells/well and left to adhere overnight before treatment with the indicated concentrations of Zantrene for 96h. Wells had fresh media added and were left for an additional 96h to assess drug recovery.

Clonogenicity was assessed using crystal violet staining. Image of plate used for analysis (left). Colony area normalised to the untreated (UT) wells (right). Mean +/-SEM, n=3. All ccRCC cell lines were more sensitive to Zantrene (i.e. lower IC50 values) in the clonogenic cell growth assay (Table 2 & Figure 4). Similar sensitivity trends were observed as those seen in the cytotoxicity assay (Table 1). The A-704 cells remained the most resistant to Zantrene and the HEK293, ACHN, KMRC-1 and A-498 cell lines were the most sensitive. Interestingly, the Caki-1 ccRCC cells showed more than 10 times greater sensitive to Zantrene in the clonogenic assay than in the cytotoxicity assay (60nM verses 659nM) suggesting Zantrene may be a potent inhibitor of ccRCC growth at concentrations below the cytotoxic level. As seen in the cytotoxicity assays, the RCC-4 EV (VHL mutant) cells were significantly more sensitive (2.9x) to Zantrene than the wild-type RCC-4 VHL rescue cells (Table 2 & Figure 5). Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com 7 Figure 5. Association of Zantrene sensitivity and VHL status as assessed using clonogenicity assays. Colonies observed for the RCC4 EV and RCC4 VHL rescue cell lines.Cells were treated as described in Figure 4. NS, not significant, unpaired t-test. n=4, *p<0.05, paired t-test.

Table 2. Clonogenic IC50 of Zantrene in human renal cell lines. Cell Line Renal Cell Type Zantrene IC50 (nM) HK-2 Non-tumourigenic cortex/proximal tubule 217 HEK293 Tumourigenic embryonic kidney 46 ACHN Metastatic (pleural effusion) 53 Caki-1 Adenocarcinoma (metastatic) 60 Caki-2 Adenocarcinoma 116 769-P ccRCC 84 786-O ccRCC 229 A-704 ccRCC 750 KMRC-1 ccRCC 60 A-498 ccRCC 46 RCC4 EV (VHL mutant) ccRCC 167 RCC4 VHL (VHL widetype) ccRCC 483 Blue: non-cancer cell lines; Black: kidney cancer cell lines. Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com 8 3.

The FTO inhibitor Dac51 is less effective at killing ccRCC cells than Zantrene The cytotoxic sensitivity of five ccRCC cell lines to the structurally distinct FTO inhibitor, Dac519, was examined. A significantly higher concentration of Dac51 than Zantrene was required to kill all five ccRCC cell lines (Figure 6 & Table 3). Figure 6. Cytotoxicity of single agent Zantrene and DAC51 in clear cell renal cell carcinoma cell lines. 786-O, Caki-1, Caki-2, RCC4 EV and RCC4 VHL ccRCC cells were treated for 72h with the indicated drug concentrations of (A) Zantrene or (B) DAC51. Cell viability was determined using the resazurin metabolic assay and visual inspection. Cell viability is expressed as a percentage of untreated control cells. Mean +/-SEM, n=3. A number of interesting differences were noted between the two FTO inhibitor agents. The 786-O cell line was the most sensitive to Dac51, yet the least sensitive to Zantrene.

In contrast, the Caki-2 cells were the most sensitive to Zantrene, but the least sensitive to Dac51 (Table 3). Unlike Zantrene, Dac51 was more effective at killing the RCC4 VHL wildtype cell line than the corresponding mutant RCC4 EV cell line. In addition, the cytotoxic IC50 values for Dac51 ranged between 14x to 50x its reported IC50 values for FTO inhibition (0.4µM)9, suggesting that the modest Dac51 cytotoxic activity may reflect an offtarget effect.